Overview

Genome-wide association studies (GWAS) are large-scale analyses that scan the genomes of thousands of individuals to identify genetic variants associated with particular traits or diseases. By comparing allele frequencies between cases and controls, GWAS can pinpoint genomic loci that contribute to complex phenotypes such as height, diabetes, or cardiovascular disease. The approach is hypothesis-free — it examines millions of SNPs across the genome without prior assumptions about which genes are involved. Since the first landmark GWAS in 2005, this method has uncovered tens of thousands of trait-associated loci.

Methods

A typical GWAS proceeds through several stages. First, study participants are genotyped using SNP arrays or DNA sequencing. After quality control (filtering SNPs by call rate, Hardy-Weinberg equilibrium, and minor allele frequency), the data undergo imputation to infer untyped variants using reference panels. Association testing is performed using logistic regression or linear mixed models that correct for population stratification. The stringent genome-wide significance threshold (p < 5 × 10⁻⁸) accounts for multiple testing across millions of SNPs. Results are visualized in Manhattan plots showing chromosomal positions versus significance, and Q-Q plots assess systematic bias.

Applications

GWAS has transformed our understanding of common disease genetics. It has identified hundreds of loci for type 2 diabetes, coronary artery disease, and autoimmune disorders, many pointing to unexpected biological pathways. In cancer research, GWAS loci have revealed new susceptibility genes and potential cancer biochemistry targets. However, translating GWAS signals into causal mechanisms remains challenging, as most associated variants lie in non-coding regions. Post-GWAS analyses include fine-mapping, functional annotation, and Mendelian randomization to establish causality and explore clinical biochemistry relevance.